文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

糖尿病肾病的最新综述:诊断、预后、治疗目标和最新指南。

An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.

机构信息

Centre for Kidney Research and Innovation, University of Nottingham, Nottingham, UK.

Department of Renal Medicine, Royal Derby Hospital, Derby, UK.

出版信息

Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15. doi: 10.1111/dom.14007.


DOI:10.1111/dom.14007
PMID:32267079
Abstract

Diabetic nephropathy (DN) is a major healthcare challenge. It occurs in up to 50% of those living with diabetes, is a major cause of end-stage kidney disease (ESKD) that requires treatment with dialysis or renal transplantation, and is associated with significantly increased cardiovascular morbidity and mortality. DN is a clinical syndrome characterized by persistent albuminuria and a progressive decline in renal function, but it is increasingly recognized that the presentation and clinical course of kidney disease in diabetes is heterogeneous. The term diabetic kidney disease (DKD) is now commonly used to encompass the spectrum of people with diabetes who have either albuminuria or reductions in renal function. In this article, the clinical presentation and approach to diagnosis of DKD will be discussed, as will its prognosis. The general principles of management of DKD will also be reviewed with reference to current international guidelines.

摘要

糖尿病肾病(DN)是一个主要的医疗保健挑战。它发生在多达 50%的糖尿病患者中,是导致终末期肾病(ESKD)的主要原因,需要进行透析或肾移植治疗,并且与心血管发病率和死亡率的显著增加相关。DN 是一种临床综合征,其特征为持续的白蛋白尿和肾功能进行性下降,但现在越来越多的人认识到糖尿病患者的肾脏疾病的表现和临床过程是异质的。现在,术语“糖尿病肾病(DKD)”通常用于包含患有白蛋白尿或肾功能降低的糖尿病患者。本文将讨论 DKD 的临床表现和诊断方法,以及其预后。还将参考当前的国际指南,回顾 DKD 的一般管理原则。

相似文献

[1]
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.

Diabetes Obes Metab. 2020-4

[2]
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".

Nutr Metab Cardiovasc Dis. 2019-10-2

[3]
[Managing diabetic kidney disease].

Ther Umsch. 2020-9

[4]
Diabetic Nephropathy: An Overview.

Methods Mol Biol. 2020

[5]
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".

J Nephrol. 2020-2

[6]
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Am J Kidney Dis. 2018-5-18

[7]
[Recommendations for the management of diabetic patients with nephropathy].

MMW Fortschr Med. 2005-5-26

[8]
Update of pathophysiology and management of diabetic kidney disease.

J Formos Med Assoc. 2018-3-2

[9]
Early diabetic nephropathy: assessment and potential therapeutic interventions.

Diabetes Care. 1986

[10]
Risk factors for rapid kidney function decline in diabetes patients.

Ren Fail. 2024-12

引用本文的文献

[1]
Xiaoke Decoction Inhibits COX-2-Mediated LDLr Pathway Dysfunction and Protects Renal Function in Diabetic Nephropathy Rats.

Curr Med Sci. 2025-9-5

[2]
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progression.

BMC Nephrol. 2025-8-31

[3]
Exploring the Proteomic Signature of Diabetic Nephropathy: Implications for Early Diagnosis and Treatment.

Life (Basel). 2025-8-19

[4]
Hypoxia-associated genes and metabolic abnormalities in peripheral blood mononuclear cells of type 1 diabetes mellitus patients.

Hereditas. 2025-8-21

[5]
Overexpression of PON1 reduces high glucose induced renal tubular epithelial cell injury by activating PPARγ signaling pathway to alleviate diabetes nephropathy.

Arch Endocrinol Metab. 2025-8-20

[6]
Discordance of diabetic retinopathy severity in a cohort of diabetic nephropathy patients: a cross-sectional case-control study in a new Mexican population of type 2 diabetes.

Front Endocrinol (Lausanne). 2025-8-1

[7]
Diabetes and calcific aortic valve disease: controversy of clinical outcomes in diabetes after aortic valve replacement.

Front Endocrinol (Lausanne). 2025-7-30

[8]
Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study.

Int J Mol Sci. 2025-8-1

[9]
Research progress on non-coding RNA regulatory networks and targeted therapy in diabetic nephropathy.

Front Endocrinol (Lausanne). 2025-7-29

[10]
Daidzein alleviates renal damage in streptozotocin induced diabetes in Sprague Dawley rats by targeting NOX-4 and RAC-1.

J Mol Histol. 2025-8-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索